Drug Profile


Alternative Names: BM 211290; Fozivudine tidoxil; FZT; HDP 99.0002; HDP 990002; W 09726867

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Heidelberg Pharma
  • Class Antivirals; Deoxyribonucleosides; Dideoxynucleosides; Lipids; Pyrimidine nucleosides
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 09 Oct 2017 Heidelberg Pharma is now called Heidelberg Pharma Research
  • 18 May 2005 Fozivudine is available for licensing (
  • 15 Jun 2004 Phase-II clinical trials in HIV infections treatment in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top